This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Srinivasan, D. Articles by Plattner, R. Search for Related Content PubMed PubMed Citation Articles by Srinivasan, D. Articles by Plattner, R.

Activation of Abl Tyrosine Kinases Promotes Invasion of Aggressive Breast Cancer Cells

Department of Molecular and Biomedical Pharmacology, University of Kentucky School of Medicine, Lexington, Kentucky

Requests for reprints: Rina Plattner, Department of Molecular and Biomedical Pharmacology, University of Kentucky School of Medicine, 800 Rose Street, Combs Research Building, Room 209, Lexington, KY 40536. Phone: 859-323-4778; Fax: 859-257-8940; E-mail: rplat2{at}uky.edu.

The Abl family of nonreceptor tyrosine kinases consists of two related proteins, c-Abl and Abl-related gene (Arg). Activated forms of the Abl kinases (BCR-Abl, Tel-Abl, and Tel-Arg) induce the development of human leukemia; it is not known, however, whether Abl kinases are activated in solid tumors or whether they contribute to tumor development or progression. Previously, we showed that Abl kinases are activated downstream of growth factor receptors, Src family kinases, and phospholipase C1 (PLC1) in fibroblasts and influence growth factor–mediated proliferation, membrane ruffling, and migration. Growth factor receptors, Src kinases, and PLC1 are deregulated in many solid tumors and drive tumor invasion and metastasis. In this study, we found that Abl kinases are constitutively activated, in highly invasive breast cancer cell lines, downstream of deregulated ErbB receptors and Src kinases. Furthermore, activation of Abl kinases promotes breast cancer cell invasion, as treatment of cells with the Abl kinase inhibitor, STI571, or silencing c-Abl and Arg expression with RNA interference dramatically inhibits Matrigel invasion. This is the first evidence that (a) Abl kinases are deregulated and activated in a nonhematopoietic cancer, (b) activation of Abl kinases in breast cancer cells occurs via a novel mechanism, and (c) constitutive activation of Abl kinases promotes invasion of breast cancer cells. These data suggest that pharmacologic inhibitors targeted against Abl kinases could potentially be useful in preventing breast cancer progression in tumors harboring activated Abl kinases. (Cancer Res 2006; 66(11): 5648-55)

This article has been cited by other articles:

				S. Mitra, C. Beach, G.-S. Feng, and R. Plattner SHP-2 is a novel target of Abl kinases during cell proliferation J. Cell Sci., October 15, 2008; 121(20): 3335 - 3346. [Abstract] [Full Text] [PDF]

				R. Vitali, C. Mancini, V. Cesi, B. Tanno, M. Mancuso, G. Bossi, Y. Zhang, R. V. Martinez, B. Calabretta, C. Dominici, et al. Slug (SNAI2) Down-Regulation by RNA Interference Facilitates Apoptosis and Inhibits Invasive Growth in Neuroblastoma Preclinical Models Clin. Cancer Res., July 15, 2008; 14(14): 4622 - 4630. [Abstract] [Full Text] [PDF]

				Y. Huang, E. O. Comiskey, R. S. Dupree, S. Li, A. J. Koleske, and J. K. Burkhardt The c-Abl tyrosine kinase regulates actin remodeling at the immune synapse Blood, July 1, 2008; 112(1): 111 - 119. [Abstract] [Full Text] [PDF]

				M. Milstein, C. K. Mooser, H. Hu, M. Fejzo, D. Slamon, L. Goodglick, S. Dry, and J. Colicelli RIN1 Is a Breast Tumor Suppressor Gene Cancer Res., December 15, 2007; 67(24): 11510 - 11516. [Abstract] [Full Text] [PDF]

				J. Suzuki and T. Shishido Regulation of Cellular Transformation by Oncogenic and Normal Abl Kinases J. Biochem., April 1, 2007; 141(4): 453 - 458. [Abstract] [Full Text] [PDF]

				B. Tanos and A. M. Pendergast Abl Tyrosine Kinase Regulates Endocytosis of the Epidermal Growth Factor Receptor J. Biol. Chem., October 27, 2006; 281(43): 32714 - 32723. [Abstract] [Full Text] [PDF]